Tenax Therapeutics is focused on developing innovative therapies for pulmonary hypertension (PH), particularly targeting the unmet medical needs associated with this condition. Their approach emphasizes patient-centric and precision medicine, which aims to tailor treatments to individual patient profiles. The company employs innovative clinical trial designs that enhance efficiency and reduce the number of patients required for trials, thereby accelerating the development of new therapies. This strategic focus is particularly relevant in the context of pulmonary hypertension, where existing treatments are limited and survival rates remain low.

The company's pipeline includes promising products such as TNX-201, an oral formulation of enteric-coated imatinib, which has shown effectiveness in treating pulmonary arterial hypertension (PAH) in previous trials. This novel formulation addresses issues of gastric intolerance associated with traditional imatinib. Additionally, Tenax is developing TNX-103, an oral version of levosimendan, which has been proven safe and effective for acute heart failure in numerous countries. This drug is particularly noteworthy for its unique mechanism of action, which has demonstrated efficacy in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Both products represent potential breakthroughs in disease-modifying treatments for these challenging conditions.

United States

Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need.

Tenax Therapeutics

Company Details